Orchestra Biomed Holdings vs Stereotaxis
Orchestra Biomed Holdings and Stereotaxis are similar in size: $33.5m and $32.4m of revenue in their latest fiscal years. Orchestra Biomed Holdings grew faster (1169.2% against 20.3%). Stereotaxis kept more of each dollar of sales as profit: a net margin of -66.8% against -157.4%.
| Latest fiscal year | Orchestra Biomed HoldingsOBIO, 2025 | StereotaxisSTXS, 2025 |
|---|---|---|
| Revenue | $33.5m | $32.4m |
| Revenue growth | 1169.2% | 20.3% |
| Net income | −$52.7m | −$21.6m |
| Operating margin | — | — |
| Net margin | -157.4% | -66.8% |
| Return on equity | -121.8% | — |
| Free cash flow | −$49.5m | −$13.8m |
| Cash | $34.7m | $13.4m |
| Total debt | $15.0m | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | 0.0% |
| Share buybacks | — | — |
| Employees | 86 | 131 |
| Market value | $338m | $81.6m |
| Price vs our value range | — | — |
| Moat score | — | 22 (Weak) |
| Insider trades, 12 months | 9 buys, 6 sales | 2 buys, 0 sales |